GTS Securities’s INmune Bio INMB Stock Holding History

GTS Securities’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-35,629	Closed	-$82.3K	–	1571
2025 Q2	$82.3K	Buy	+35,629	New	+$261K	﹤0.01%	1169

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GTS Securities's INMB Position: Q3 2025 in Review

GTS Securities sold out of INmune Bio (INMB) in Q3 2025, closing a stake of 35,629 shares — an estimated $82.3K sold.

GTS Securities first reported a position in INMB in Q2 2025 and held it in 1 quarter. The position peaked at $82.3K in Q2 2025. 73 funds tracked by Wall St. Rank hold INMB as of Q3 2025.

GTS Securities reported no remaining INmune Bio position as of Q3 2025 after selling out during the quarter.
GTS Securities sold 35,629 INmune Bio shares in Q3 2025, an estimated $82.3K.
GTS Securities first reported a position in INmune Bio in Q2 2025 and held it in 1 quarter.
GTS Securities's INmune Bio position peaked at $82.3K in Q2 2025.
73 funds tracked by Wall St. Rank held INmune Bio as of Q3 2025.

Based on GTS Securities's 13F filing for Q3 2025, filed 14 Nov 2025.